Efficacy of Moxifloxacin Combined with HRZE Chemotherapy Regimen in the Treatment of Pulmonary Tuberculosis and its Impact on Serum PCT and hs-CRP Levels
Abstract：【Objective】 This study aimed to investigate the efficacy of moxifloxacin combined with isoniazid,rifampicin,pyrazinamide,and ethambutol (HRZE) chemotherapy regimen in the treatment of pulmonary tuberculosis and explore effects of the therapy on serum procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) levels in patients. 【Methods】 A total of 80 patients with pulmonary tuberculosis admitted to our hospital were randomly divided into an observation group and a control group,with 40 patients in each group. Both groups received HRZE anti-tuberculosis chemotherapy regimen,while the observation group received additional moxifloxacin treatment. The treatment duration for both groups was 4 months. The sputum smear conversion rate and chest CT evaluation were compared between the two groups. Additionally,the levels of PCT and hs-CRP,immune function markers [CD8+ T cells,CD4+ T cells,immunoglobulin G (IgG),immunoglobulin A (IgA)],and occurrence of adverse reactions were compared between the two groups. 【Results】 The sputum smear conversion rate in the observation group was 92.50% (37/40),significantly higher than that in the control group (75.00%,30/40) (P<0.05). The total absorption rate on chest CT in the observation group was 97.5% (39/40),which was significantly higher than that in the control group (77.50%,31/40) (P<0.05). After treatment,the serum levels of PCT and hs-CRP in both groups were significantly lower than before treatment (P<0.05),and the observation group had significantly lower levels of PCT and hs-CRP compared to the control group (P<0.05). The levels of CD4+,IgG,and IgA were significantly higher,and CD8+ level was lower in both groups after treatment compared to before treatment,with statistical significance (P<0.05). Moreover,the observation group had significantly higher levels of IgA,CD4+ and IgG and lower CD8+ level compared to the control group (P<0.05). The overall incidence of adverse reactions after treatment showed no significant difference between the two groups (P>0.05). 【Conclusion】 Moxifloxacin combined with HRZE chemotherapy regimen demonstrates significant efficacy in the treatment of pulmonary tuberculosis,effectively improves clinical outcomes,enhances patient immune capacity,and is clinically safe. Therefore,it can be widely applied in clinical practice.
丁玲, 吕恒毅, 田艳茹. 莫西沙星联合HRZE化疗方案治疗肺结核的疗效及对血清PCT、hs-CRP水平的影响[J]. 医学临床研究, 2023, 40(6): 892-894.
DING Ling, LYU Heng-yi, TIAN Yan-ru. Efficacy of Moxifloxacin Combined with HRZE Chemotherapy Regimen in the Treatment of Pulmonary Tuberculosis and its Impact on Serum PCT and hs-CRP Levels. JOURNAL OF CLINICAL RESEARCH, 2023, 40(6): 892-894.
2023, Vol. 40 
